Document is current
Any future updates will be listed below
-
Authors
Saber, Ralph http://orcid.org/0000-0003-4770-8631
Henault, David
Messaoudi, Nouredin
Rebolledo, Rolando
Montagnon, Emmanuel
Soucy, Geneviève
Stagg, John
Tang, An
Turcotte, Simon http://orcid.org/0000-0002-9003-812X
Kadoury, Samuel
-
Funding
Funding for this research was provided by:
Canada Excellence Research Chairs, Government of Canada
National Science and Engineering Research Council of Canada (RGPIN-2020-06558)
Université de Montréal Roger Des Groseillers Research Chair in Hepatopancreatobiliary Surgical Oncology
Fonds de Recherche du Québec - Santé
FRQ-S Young Clinician Scientist Seed Grant (No. 32633)
FRQS Clinician Scientist Junior-1&2 Salary Award (No. 30861, No. 298832)
Institut du Cancer de Montréal establishment award
FRQ-S phase 1 award for medical resident engaged in clinician-scientist training
International Hepato-Pancreato-Biliary Association (IHPBA) Kenneth Warren Research Fellowship and Ethicon Inc.
- License Information
-
More Information
Article History
Received: 9 March 2023
Accepted: 30 April 2023
First Online: 27 July 2023
Declarations
:
: This study was approved by the Centre Hospitalier de l’Université de Montréal (CHUM) institutional review board (No. 16.262) and was performed in accordance with the Declaration of Helsinki. All patients provided informed written consent to participate to the CHUM hepatopancreatobiliary cancer biobank and prospective registry associated with this study (No. 09.237).
: Does not apply.
: Outside the submitted work, ST has received consultant fees from Bristol Myers Squibb and Turnstone Biologics, speaking fees from Celgene and Astra Zeneca, and has research funding from Lovance Biotherapeutics and Turnstone Biologics. JS is a permanent member of the scientific advisory board of Surface Oncology and holds stocks of Surface Oncology.
